Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273726 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
A Phase 3 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 741
- Enrollment target
NCT02273726: Completed Phase 3 study, sponsored by Kyntra Bio.
NCT02273726 is a Phase 3 study that has completed, run by Kyntra Bio. The registered enrollment target is 741 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02273726, a Phase 3 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 741 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
Primary Outcome
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment rely
Interventions
- DRUG Epoetin Alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 3 |
What the finished NCT02273726 record still lists
NCT02273726 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Alfa is the first listed.
NCT02273726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02273726 about?
NCT02273726 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis". The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
What is the current status of trial NCT02273726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 741 participants. The study started on 2015-01-15. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT02273726?
The interventions under investigation include: Epoetin Alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02273726?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02273726's enrollment target sits among peer trials
741 476th of 2000 higher than 1,524 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI